• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Pharmacogenomics and Coagulation Disorders

        互联网

        300
        The term pharmacogenetics, first introduced by Vogel in 1959 (1 ) is defined as the analysis of inherited factors that define an individual’s response to a drug, and generally refers to monogenetic variants that affect drug response. Pharmacogenetics refers to the monogenetic variants that affect drug response, and aims to deliver the right drug to the correct patient at the correct dosage by using DNA information. Pharmacogenomics refers to the entire library of genes that determine drug efficacy and safety. There are approx 3 billion basepairs in the human genome, which code for at least 30,000 genes. Although the majority of basepairs are identical from individual to individual, only 0.1% of the basepairs contribute to individual differences. Three consecutive basepairs form a codon that specifies the amino acids that constitute the protein, because of substantial redundancy, and two or more codons code for the same amino acid. Genes represent a series of codons that specifies a particular protein. At each gene locus, an individual carries two alleles—one from each parent. If there are two identical alleles, it is referred to as a homozygous genotype; if the alleles are different, it is heterozygous. Genetic variations usually occur as single-nucleotide polymorphisms (SNP) on average at least once every 1000 basepairs, accounting for approx 3 million basepairs distributed throughout the entire genome. Genetic variations that occur at a frequency of at least 1% in the human population are referred to as polymorphisms.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序